Recent data suggest that HER2 status (i.e., the amount of HER2 protein in HER2 overexpressing tumours) may influence the tumour immune microenvironment, and response to HER2-targeted therapies can be predicted by immune cell compositions [179]. Here, ERBB2 is linked to neoplasm.